The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 21, 2026 | Aminov Erez | CEO and Chairman, Director | Grant(A) | 2.0M | — | — |
| May 21, 2026 | Aminov Erez | CEO and Chairman, Director | Disposed to issuer(D) | 2.0M | — | — |
| May 21, 2026 | Aminov Erez | CEO and Chairman, Director | Grant(A) | 2.0M | — | — |
| May 21, 2026 | Aminov Erez | CEO and Chairman, Director | Disposed to issuer(D) | 2.0M | — | — |
| May 21, 2026 | Del Giudice Matthew Paul | Director | Grant(A) | 25K | — | — |
| May 21, 2026 | Del Giudice Matthew Paul | Director | Disposed to issuer(D) | 25K | — | — |
| May 21, 2026 | MacPherson Edward Clouston | Director | Grant(A) | 25K | — | — |
| May 21, 2026 | MacPherson Edward Clouston | Director | Disposed to issuer(D) | 25K | — | — |
| May 21, 2026 | Whalen Matthew Pratt | Director | Grant(A) | 25K | — | — |
| May 21, 2026 | Whalen Matthew Pratt | Director | Disposed to issuer(D) | 25K | — | — |
| Apr 22, 2026 | Aminov Erez | CEO and Chairman, Director | Other(J) | 7.3M | $1.37 | $10.0M |
| Apr 16, 2026 | Whalen Matthew Pratt | Director | Grant(A) | 50K | — | $0 |
| Apr 16, 2026 | MacPherson Edward Clouston | Director | Grant(A) | 50K | — | $0 |
| Apr 16, 2026 | Del Giudice Matthew Paul | Director | Grant(A) | 50K | — | $0 |
| May 28, 2025 | Aminov Erez | CEO and Chairman, Director | Grant(A) | 2.0M | — | $0 |
| May 28, 2025 | Aminov Erez | CEO and Chairman, Director | Grant(A) | 400K | — | $0 |
| Nov 21, 2024 | Bay Shore Trust | 10% Owner | Gift(G) | 100K | — | — |
| Aug 27, 2024 | Whalen Matthew Pratt | Director | Grant(A) | 25K | — | $0 |
| Aug 27, 2024 | Del Giudice Matthew Paul | Director | Grant(A) | 25K | — | $0 |
| Aug 27, 2024 | Aminov Erez | CEO & Chairman, Director | Grant(A) | 2.0M | — | $0 |
| Aug 27, 2024 | MacPherson Edward Clouston | Director | Grant(A) | 25K | — | $0 |
| Aug 27, 2024 | Jerman Michael Allen | Director | Grant(A) | 25K | — | $0 |
| Aug 27, 2024 | Yanez Michelle | Chief Financial Officer | Grant(A) | 200K | — | $0 |
| Feb 13, 2024 | McNulty Brian Patrick | 10% Owner | Buy(P) | 49K | $7.00 | $343K |
| Feb 13, 2024 | McNulty Brian Patrick | 10% Owner | Buy(P) | 40K | $7.00 | $280K |
| Feb 13, 2024 | McNulty Brian Patrick | 10% Owner | Buy(P) | 49K | $7.00 | $343K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Telomir Pharmaceuticals, Inc., SEC CIK 0001971532. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under TELO and shows every filing by that issuer.
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-05. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for TELO